Journal article
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
LK Petersen, J Restrepo, ED Moreira, OE Iversen, P Pitisuttithum, P Van Damme, EA Joura, SE Olsson, D Ferris, S Block, AR Giuliano, X Bosch, S Pils, J Cuzick, SM Garland, W Huh, SK Kjaer, OM Bautista, D Hyatt, R Maansson Show all
Papillomavirus Research | ELSEVIER SCIENCE BV | Published : 2017
Abstract
Background The immunogenicity profile of the 9-valent HPV (9vHPV) vaccine was evaluated across five phase III clinical studies conducted in girls and boys 9–15 years of age and young women 16–26 years of age. The effect of baseline characteristics of subjects on vaccine-induced HPV antibody responses was assessed. Methods Immunogenicity data from 11,304 subjects who received ≥1 dose of 9vHPV vaccine in five Phase III studies were analyzed. Vaccine was administered as a 3-dose regimen. HPV antibody titers were assessed 1 month after dose 3 using a competitive Luminex immunoassay and summarized as geometric mean titers (GMTs). Covariates examined were age, gender, race, region of residence, an..
View full abstractGrants
Awarded by Cancer Research UK
Funding Acknowledgements
This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA (sponsor). All co-authors approved the final version of the manuscript.